1. Parkash R, Magee K, McMullen M et al (2019) The Canadian Community Utilization of Stroke Prevention Study in Atrial Fibrillation in the Emergency Department (C-CUSP ED). Ann Emerg Med 73:382–392
2. European Society of Cardiology. 2020 Atrial Fibrillation ESC Guidelines: Implication for practice. Available at: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management.
3. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al (2014) Comparison on the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet 383(9921):955–962
4. Informe de posicionamiento terapéutico UT/V4/23122013: Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales (NACO) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad, Agencia Española de Medicamentos y Productos Sanitarios; 2013. Available at: http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/home.htmKea B, Amber L, Olshansky B, Malveau S, Fu R, Raitt M et al. Stroke-prophylaxis after a new emergency department diagnosis of atrial fibrillation. J Am Coll Cardiol 2018;72(4): 471–472.
5. Sandhu RK, Bakal JA, Ezekowitz JA et al (2011) The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. Am Heart J 161:986–992